Description

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) discusses antisense oligonucleotides-based therapy for treating cystic fibrosis, novel therapeutics for loculated pleural effusion, medicinal food to maintain lung health, and developing novel therapeutics with modified thioredoxin. The TOE also focuses on developing novel therapeutics based on targeted protein degradation, protein derived from alternative sources for pet wellness, a probiotic artisan ice cream to treat gastro-intestinal issues, exosome therapeutics for delivery of drugs/vaccines, and circular RNA therapeutics for genetic and autoimmune diseases.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Antisense oligonucleotides, cystic fibrosis, loculated pleural effusion, lung health, thioredoxin, targeted protein degradation, protein, probiotics, gastro-intestinal issues, exosome therapeutics, drug delivery, circular RNA therapeutics, genetic and autoimmune diseases, pet health